An analytics-enabled, digital platform will be co-developed by GE Healthcare and Roche Holding under a new partnership agreement for streamlining and improving clinical decision-making and personalized cancer and critical care treatments. The software tool, which will be co-marketed by the companies' existing sales force, will enable advanced analytics to be applied to in vitro data from Roche's biomarker, genomics, tissue pathology and sequencing portfolio and to in vivo data from GE's imaging and monitoring equipment.
GE teams up with Roche on data analytics platform development
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.